AURKA and melanoma: A recent study of Aurora A kinase inhibitor MLN8054, MEK inhibitor trametinib, and BRAF inhibitor dabrafenib evaluated various combinations of these drugs in BRAF mutant melanoma cell lines (Caputo et al., 2014).